Verrica Inks Israeli Deal for Molluscum Treatment YCANTH
Event summary
- Verrica granted Medomie exclusive rights to seek regulatory approval and distribute YCANTH in Israel under a new agreement.
- Verrica will manufacture YCANTH, supply it to Medomie, and receive 60% of net selling price from Israeli sales.
- Up to $8.2 million in regulatory and commercial milestones are available to Verrica under the deal.
- YCANTH is FDA-approved for molluscum contagiosum in the U.S. and approved in Japan.
The big picture
This deal represents Verrica's strategic push into international markets beyond the U.S. and Japan, where YCANTH is already approved. The partnership with Medomie aligns with Verrica's goal of establishing YCANTH as a standard treatment for molluscum contagiosum globally. The agreement also highlights the growing trend of pharmaceutical companies leveraging local partners to navigate regulatory and commercial landscapes in different regions.
What we're watching
- Regulatory Progress
- Whether Medomie can secure marketing authorization for YCANTH in Israel and the timeline for approval.
- Commercial Execution
- How effectively Medomie can commercialize YCANTH in the Israeli market given its focus on innovative treatments.
- Revenue Impact
- The contribution of Israeli sales to Verrica's global revenue, particularly as it seeks to expand YCANTH's reach internationally.
Related topics